News

21.05.2013 - SuppreMol raises EUR 9.5 million in Extended Series D Financing Round

SuppreMol GmbH today announces the second closing of a Series D financing round receiving EUR 9.5 million with BioMedPartners AG as co-lead investor.

17.10.2012 - Spinelab announces Exclusive Distribution Agreement with Biomet for Spain and Portugal

Spinelab announces the signature of an exclusive distribution agreement with Biomet.

31.05.2012 - Spinelab raises CHF 4.7 million in Series C financing round

Spinelab AG announces that it has raised Swiss francs 4.7 million in a Series C financing round. Lead investors are BioMedInvest and VI Partners.

14.03.2012 - Okairos initiates Phase I/II clinical trial for potential first-in-class hepatitis C vaccine

Okairos today announced the initiation of a Phase I/II clinical trial evaluating its vaccine against the hepatitis C virus (HCV).

14.02.2012 - SuppreMol with positive interim Phase Ib/IIa results on SM101 in ITP trials

SuppreMol GmbH today announces positive interim results of the Phase Ib/IIa clinical trial of SM101 to treat Primary Immune Thrombocytopenia (ITP).

02.10.2011 - Symetis receives CE Mark for its ACURATE TA transapical TAVI system

Symetis SA announced during the Techno-College at the EACTS meeting that it received CE Mark Certification for its ACURATE TA transapical TAVI system.

13.09.2011 - Okairòs AG strengthens its board of directors and management team

Okairòs AG today announced the appointment of two pharmaceutical industry leaders to its board of directors and the hiring of a Chief Operating Officer.

06.05.2011 - Spinelab presents its spine implant system Elaspine™

Spinelab today announces that its newly developed spine implant system Elaspine™ is presented the first time at the Spine Technology Summit on in Napa Valley, USA.

24.01.2011 - SuppreMol completes successful Pre-IND Meeting with FDA

SuppreMol GmbH today announced that it has successfully completed a pre-IND meeting with the U.S. FDA for its lead compund SM101.

24.01.2011 - Erfolgreiches Pre-IND-Meeting zwischen der SuppreMol GmbH und der amerikanischen Zulassungsbehörde FDA

Die SuppreMol GmbH hat ein Treffen mit der amerikanischen Food and Drug Administration (FDA) zur Vorbereitung weiterer klinischer Prüfungen von SM101 erfolgreich abgeschlossen.

01.12.2010 - SuppreMol Series C-Finanzierungsrunde

SuppreMol GmbH schliesst eine Series C-Finanzierungsrunde über EUR 15.5 Millionen mit BioMedPartners AG als Co-Lead ab.

01.12.2010 - SuppreMol closes Series C Financing Round

SuppreMol GmbH today announced the closing of a EUR 15.5 Million Series C financing round with BioMedPartners AG as co-lead.

14.09.2010 - Okairòs raises EUR 16 Mio. in Series B Financing

Okairòs closes EUR 16 Mio. Series B financing round led by Versant Ventures and joined by Boehringer Ingelheim Venture Fund. BioMedPartners and all other existing investors also participated in the round.

19.04.2010 - SuppreMol erhält Orphan Drug Status für SM101 in den USA

Die amerikanische Arzneimittelzulassungsbehörde FDA hat heute SuppreMols Medikamentenkandidaten SM101 als Arzneimittel für seltene Leiden (Orphan Drug) in der Indikation Idiopathische Thrombozytopenische Purpura (ITP) ausgewiesen.

19.04.2010 - SuppreMol receives U.S. Orphan Drug Designation for SM101

The American FDA's Office of Orphan Products Development has granted Orphan Drug Designation (ODD) for SuppreMol's lead product SM101.

12.04.2010 - Phase Ib/IIa clinical trial of SuppreMol GmbH

Today, SuppreMol GmbH announced the initiation of a Phase Ib/IIa clinical trial with its lead product SM101 in Idiopathic Thrombocytopenic Purpura (ITP).

12.04.2010 - SuppreMol beginnt klinische Phase Ib/IIa Studie mit SM101

Die SupppreMol GmbH gibt heute den Beginn einer klinischen Phase Ib/IIa Studie mit SM101 in der Indikation idiopathische thrombozytopenische Purpura (ITP) bekannt.

14.09.2009 - Acquisition of ESBATech AG by Alcon Inc.

BioMedPartners announces that it's portfolio company ESBATech AG will be acquired by Alcon Inc., the world's leading eyecare company.

12.08.2009 - Wachstumsfinanzierung der Spinelab AG

Die SHS (Gesellschaft für Beteiligungsmanagement mbH) beteiligt sich im Rahmen einer Kapitalerhöhung an der Spinelab AG.

04.05.2009 - SuppreMol beginnt klinische Phase I Studie mit SM101

SuppreMol gibt den Beginn einer klinischen Phase-I-Studie von SM101, dem am weitesten fortgeschrittenen Medikamentenkandidaten des Unternehmens, bekannt.

04.05.2009 - Start of phase I clinical trial with SM101

SuppreMol announces the start of a phase I clinical trial with its lead compound SM101.

24.03.2009 - BioMedPartners AG strengthens its management team

BioMedPartners AG has strengthened its management team with the addition of Dr. Andreas J. Schulze and the promotion of Patrick Burgermeister.

31.10.2008 - Worldwide discovery and license agreement with Allergan Inc.

Polyphor enters into an exclusive agreement with Allergan to develop PEM cytokine inhibitors for the treatment of ophthalmology.

12.08.2008 - Series A Financing Round of Lumavita AG

BioMedInvest co-leads CHF 18 Million Series A financing round of Lumavita AG.

14.07.2008 - Series B Financing Round of SuppreMol GmbH

SuppreMol closes EUR 15.7 Million Series B financing round with co-leader BioMedInvest AG.

09.07.2008 - Phase I clinical trials of POL6326

Polyphor Ltd successfully completes a Phase I clinical trial demonstrating the safety of POL6326.

09.07.2008 - Klinische Phase I mit POL6326 erfolgreich abgeschlossen

Die Phase I der klinischen Studien mit POL6326 ist erfolgreich abgeschlossen worden. Polyphor Ltd gibt bekannt, dass POL6326 sicher anwendbar und gut verträglich.

02.05.2008 - SpineLab baut Laborinfrastruktur mit dem IMES in Winterthur auf

SpineLab gibt Aufbau einer gemeinsam realisierten Laborinfrastruktur mit dem IMES bekannt.

02.05.2008 - SpineLab establishes lab facilities with IMES in Winterthur

SpineLab announced that it has established joint lab facilities with IMES in Winterthur.

14.01.2008 - Series A Financing Round of Vivendy Therapeutics AG

BioMedInvest co-leads CHF 17 Million Series A financing round of Vivendy Therapeutics AG.

27.09.2007 - SpineLab and Precimed announce strategic partnership

Precimed co-develops the minimally invasive instrument set and will handle production and logistics for DynaSpine

27.09.2007 - SpineLab und Precimed geben strategische Partnerschaft bekannt

Im Rahmen dieser Partnerschaft entwickelt Precimed ein Instrumenten-Set für minimal-invasive Operationstechniken mit und übernimmt Produktion und Logistik für DynaSpine.

24.04.2007 - SpineLab AG Erste Finanzierung

SpineLab AG Erste Finanzierung

24.04.2007 - SpineLab AG First Financing

SpineLab AG First Financing

15.02.2007 - Series A Financing Round of Okairos AG

BioMedInvest co-leads in Series A financing round of Okairos AG

30.01.2007 - Series A Financing Round of Spinelab AG

BioMedInvest leads Series A financing round of Spinelab AG

15.01.2007 - Series A Financing Round of 4-Antibody AG

BioMedInvest co-leads CHF 17 Million Series A financing of 4-Antibody AG bringing the total Series A financing to CHF 23 Million ($ 18.5Million)

03.11.2006 - IPO of Santhera Pharmaceuticals AG

IPO of Santhera Pharmaceuticals AG

05.10.2006 - Santhera Pharmaceuticals Series C Financing

BioMedInvest invests in Series C financing round of Santhera Pharmaceuticals AG

06.09.2006 - Series A Financing Round of Oncalis AG

BioMedInvest leads Series A financing round of Oncalis AG

02.08.2006 - Series B Financing Round of ESBATech AG

BioMedInvest co-leads CHF 50 Million (EUR 32 Million) Series B financing round of ESBATech AG

09.02.2006 - Series A Financing Round of Eyesense AG

BioMedInvest leads CHF 10.7 million Series A financing round of Eyesense AG

19.07.2005 - Trade Sale of GlycArt to Roche

Roche pays CHF 235 mio for GlycArt Biotechnology

04.05.2005 - IPO of Arpida

Arpida goes public